Headquartered in Durham, NC Fiscal year ends December NASDAQ: HUMA humacyte.com
Humacyte, Inc. (Nasdaq: HUMA) is a commercial-stage biotechnology platform company that develops universally implantable, bioengineered human tissues at commercial scale. The company's core technology produces acellular tissue engineered vessels (ATEVs) designed to treat a wide range of diseases, injuries, and chronic conditions. Its first commercially approved product, Symvess, is an ATEV indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss and autologous vein graft is not feasible. Symvess received FDA approval in December 2024. The company's pipeline includes late-stage clinical programs in arteriovenous access for hemodialysis and peripheral artery disease, with a planned supplemental BLA filing for the dialysis access indication. Humacyte is also advancing a coronary tissue engineered vessel (CTEV) into first-in-human clinical studies for coronary artery bypass grafting, and has preclinical programs in pediatric heart surgery, type 1 diabetes treatment, and other novel tissue applications. Several of its product candidates have received FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations. Updated
On April 18th, 24/7 Wall Street alerted investors to a recent stock purchase by Alabama Senator Tommy Tuberville of a penny stock named Humacyte (Nasdaq: HUMA). We track Congressional trades as sitting members…
Eric Bleeker Tommy Tuberville, a Republican Senator from the state of Alabama, disclosed 19 new stock trades on April 15th, and one trade in particular is causing big movements in the underlying stock. Tuberville…
Humacyte, Inc. (Nasdaq: HUMA) is a commercial-stage biotechnology platform company that develops universally implantable, bioengineered human tissues at commercial scale.
The Wall Street consensus 12-month price target for HUMA is $1.85.
